These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18653914)

  • 1. Tetany in kala azar patients treated with paromomycin.
    Thakur CP
    Indian J Med Res; 2008 May; 127(5):489-93. PubMed ID: 18653914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
    Thakur CP; Olliaro P; Gothoskar S; Bhowmick S; Choudhury BK; Prasad S; Kumar M; Verma BB
    Trans R Soc Trop Med Hyg; 1992; 86(6):615-6. PubMed ID: 1337634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
    Jha TK; Olliaro P; Thakur CP; Kanyok TP; Singhania BL; Singh IJ; Singh NK; Akhoury S; Jha S
    BMJ; 1998 Apr; 316(7139):1200-5. PubMed ID: 9583927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in kala-azar patients with severe thrombocytopenia caused by sodium antimony gluconate & miltefosine.
    Thakur CP; Kumar A; Mitra G; Thakur S; Thakur M
    Indian J Med Res; 2007 Jul; 126(1):73-5. PubMed ID: 17890828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP; Thakur S; Narayan S; Sinha A
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with roxithromycin in visceral leishmaniasis in north Bihar.
    Lal SK; Lal R; Lal S; Lal R; Lal BN
    J Assoc Physicians India; 1996 Sep; 44(9):615-7. PubMed ID: 9251373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paromomycin.
    Davidson RN; den Boer M; Ritmeijer K
    Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):653-60. PubMed ID: 18947845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication.
    Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM
    Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug unresponsiveness & combination therapy for kala-azar.
    Jha TK
    Indian J Med Res; 2006 Mar; 123(3):389-98. PubMed ID: 16778318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh.
    Salam MA; Mondal D; Kabir M; Ekram AR; Haque R
    Acta Trop; 2010 Jan; 113(1):52-5. PubMed ID: 19769932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of kala-azar: old and new options.
    Zijlstra EE
    Trop Geogr Med; 1992 Jul; 44(3):288. PubMed ID: 1455546
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.
    Roseboom IC; Thijssen B; Rosing H; Alves F; Younis BM; Musa AM; Beijnen JH; Dorlo TPC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123494. PubMed ID: 36219923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy in kala-azar.
    Rees PH; Kager PA; Kyambi JM; Ayim EN; Bhatt KM; Schattenkerk JK
    Trop Geogr Med; 1984 Sep; 36(3):285-92. PubMed ID: 6506208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicoepidemiological profile of kala azar patients in Delhi.
    Mittal V; Bhatia R; Sehgal S
    J Commun Dis; 1989 Dec; 21(4):255-61. PubMed ID: 2638373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.